SEC Tracker
Get the app

Vaxcyte PCVX

Vaxcyte reported a $297.06 million net loss for Q3 2026

Form
10-Q
Filed
Importance
Notable
  1. Net loss: $297.06 million for the three months ended Sep 30, 2026
  2. Diluted EPS: -$1.99 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $125.47 million at Sep 30, 2026

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Vaxcyte files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. PERRIGO PRGO public float $3.7B, Jun 27, 2025
  2. Rhythm Pharmaceuticals RYTM public float $3.8B, Jun 30, 2025
  3. Ultragenyx Pharmaceutical RARE public float $3.4B, Jun 30, 2025
  4. Avidity Biosciences RNAM public float $3.4B, Jun 30, 2025
  5. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025